Predictors of time to CR (TC) and residual survival time after CR (TC,D) under the multivariate model
Covariate . | Effect on TC . | P . | Effect on TC,D . | P . |
---|---|---|---|---|
De Novo Acute Myeloid | ||||
Leukemia* | ||||
Increasing age | TClonger | .011 | TC,D shorter | .002 |
Inv(16) or t(8;21) | TC shorter | .614 | TC,D longer | <.001 |
Other abnormal Cytogenetics | TC longer | .607 | TC,D shorter | .465 |
HDAC | TC shorter | .289 | TC,D shorter | .172 |
Fludarabine + HDAC | TC shorter | .194 | TC,D shorter | .999 |
Acute myeloid leukemia arising after AHD; RAEB, RAEB-t† | ||||
Increasing age | TC longer | .317 | TC,D shorter | .046 |
Inv(16) or t(8;21) | TC shorter | .332 | TC,D shorter | .950 |
Other abnormal Cytogenetics | TC longer | .209 | TC,D shorter | <.001 |
HDAC | TC shorter | .387 | TC,D longer | .022 |
Fludarabine + HDAC | TC shorter | .621 | TC,D longer | .062 |
Covariate . | Effect on TC . | P . | Effect on TC,D . | P . |
---|---|---|---|---|
De Novo Acute Myeloid | ||||
Leukemia* | ||||
Increasing age | TClonger | .011 | TC,D shorter | .002 |
Inv(16) or t(8;21) | TC shorter | .614 | TC,D longer | <.001 |
Other abnormal Cytogenetics | TC longer | .607 | TC,D shorter | .465 |
HDAC | TC shorter | .289 | TC,D shorter | .172 |
Fludarabine + HDAC | TC shorter | .194 | TC,D shorter | .999 |
Acute myeloid leukemia arising after AHD; RAEB, RAEB-t† | ||||
Increasing age | TC longer | .317 | TC,D shorter | .046 |
Inv(16) or t(8;21) | TC shorter | .332 | TC,D shorter | .950 |
Other abnormal Cytogenetics | TC longer | .209 | TC,D shorter | <.001 |
HDAC | TC shorter | .387 | TC,D longer | .022 |
Fludarabine + HDAC | TC shorter | .621 | TC,D longer | .062 |